Impact of different pharmacotherapies on long-term outcomes in patients with electrical storm

• Verfasst von: Schupp, Tobias [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Verfasst von: Ellguth, Dominik [VerfasserIn]
• Verfasst von: Müller, Julian [VerfasserIn]
• Verfasst von: Reiser, Linda [VerfasserIn]
• Verfasst von: Kern-Bollow, Armin [VerfasserIn]
• Verfasst von: Taton, Gabriel [VerfasserIn]
• Verfasst von: Reichelt, Thomas [VerfasserIn]
• Verfasst von: Engelke, Niko [VerfasserIn]
• Verfasst von: Kim, Seung‑Hyun [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Impact of different pharmacotherapies on long-term outcomes in patients with electrical storm
• Verf.angabe: Tobias Schupp, Michael Behnes, Dominik Ellguth, Julian Müller, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Niko Engelke, Seung-hyun Kim, Christoph Nienaber, Muharrem Akin, Kambis Mashayekhi, Thomas Bertsch, Martin Borggrefe, Ibrahim Akin
• E-Jahr: 2019
• Jahr: February 2019
• Umfang: 10 S.
• Fussnoten: Gesehen am 27.05.2019
• Titel Quelle: Enthalten in: Pharmacology
• Ort Quelle: Basel : Karger, 1968
• Jahr Quelle: 2019
• Band/Heft Quelle: 103(2019), 3-4, Seite 179-188
• ISSN Quelle: 1423-0313
• DOI: doi:10.1159/000496228
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1666360619

Abstract

Objective: The study sought to assess the long-term prognostic impact of different pharmacotherapies, including angiotensin-converting enzyme inhibitor-inhibitor/angiotensin receptor blocker (ACEi/ARB), statins, and amiodarone in patients with electrical storm (ES). Background: Data regarding the outcome of patients with ES is limited. Methods: Consecutive patients with ES from 2002 to 2016 were included. Patients on ACEi/ARB were compared to patients without ACEi/ARB, respectively, for statin and amiodarone therapy. The primary prognostic endpoint was all-cause mortality at 4 years. Secondary endpoints comprised ES recurrences, rehospitalization, and major adverse cardiac events (MACE) at 4 years. Kaplan-Meier survival curves and multivariable Cox regression analyses were applied. Results: A total of 84 consecutive patients surviving episodes of ES was included. Beta-blocker was given in 95%, ACEi/ARB in 80%, statin in 60%, and amiodarone in 54%. ACEi/ARB patients were associated with improved all-cause mortality at 4 years (mortality rate 34 vs. 65%, log rank p = 0.018; HR 0.428; 95% CI 0.208-0.881; p = 0.021), as well as improved freedom from MACE. In contrast, statin and amiodarone therapy had no impact on long-term outcomes in ES patients. Conclusion: ACEi/ARB therapy is associated with improved survival and MACE in patients with ES, whereas statins and amiodarone therapy had no impact on long-term prognostic endpoints.